The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Open accessAbstract
Myeloid-derived suppressor cells (MDSC) accumulate in most cancer patients and experimental animals with cancer. They accumulate in response to pro-inflammatory mediators and they use a variety of mechanisms to block both innate and adaptive antitumor immunity. Because of their critical role in obstructing immune responses, MDSC are a strategic obstacle to immunotherapies that require activation of the host’s cell-mediated and innate immune responses. Following a brief description of the factors that induce MDSC accumulation, this article reviews two newly discovered mechanisms that MDSC use to suppress the activation of CD4+ and CD8+ T cells. The first mechanism is MDSC sequestration of cysteine, an amino acid that T cells are unable to synthesize de novo and that they require for activation. The second mechanism is MDSC-mediated down-regulation of l-selectin. T cells must have an l-selectinhigh phenotype to home to lymph nodes and inflammatory sites where they encounter antigen and are activated. By down-regulating l-selectin on T cells, MDSC perturb T cell trafficking patterns and thereby inhibit T cell activation. Given the complexity of conditions that regulate MDSC accumulation and the variety of suppressive mechanisms used by MDSC, it is essential to understand which conditions and mechanisms are dominant so MDSC accumulation and/or activity can be targeted in individual patients to minimize MDSC-induced immune suppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Physiological functions of thioredoxin and thioredoxin reductase
Arnér, E. S. J., & Holmgren, A. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01701.x · Cited by 2,525
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
Solinas, G., Germano, G., Mantovani, A., & Allavena, P. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0609385 · Cited by 1,425
Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., & Van Ginderachter, J. A. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,174
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Cited by
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
Condamine, T., & Gabrilovich, D. I. (2011) · Trends in Immunology · doi:10.1016/j.it.2010.10.002 · Cited by 845
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Groth, C., Hu, X., Weber, R., Fleming, V., Altevogt, P., Utikal, J., & Umansky, V. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0333-1 · Cited by 839
Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H. A., & Middleton, G. W. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1028-0 · Cited by 575
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538
Heczey, A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A., Grilley, B., Liu, H., Wu, M. F., Mei, Z., Gee, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.012 · Cited by 535
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Ostrand-Rosenberg, S., & Fenselau, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701019 · Cited by 509
Self-citationMyeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Interleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
The immunology of renal cell carcinoma
Díaz-Montero, C. M., Rini, B. I., & Finke, J. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0316-3 · Cited by 442
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 438
Alizadeh, D., Trad, M., Hanke, N. T., Larmonier, C. B., Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1545 · Cited by 416
2011: the immune hallmarks of cancer
Cavallo, F., De Giovanni, C., Nanni, P., Forni, G., & Lollini, P.-L. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0968-0 · Cited by 415
Liby, K. T., & Sporn, M. B. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004846 · Cited by 405
T Cell Dysfunction and Exhaustion in Cancer
Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00017 · Cited by 385
Myeloid derived suppressor cells in human diseases
Greten, T. F., Manns, M. P., & Korangy, F. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.003 · Cited by 398
“The heterogeneity of MDSC - which explains the lack of specific markers for these cells–is, along with their multiple suppressor function, [8] a hallmark of MDSC.”
BackgroundMechanisms of Resistance to PD-1 and PD-L1 Blockade
Nowicki, T. S., Hu-Lieskovan, S., & Ribas, A. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000303 · Cited by 397
Görgün, G. T., Whitehill, G., Anderson, J. L., Hideshima, T., Maguire, C., Laubach, J., Raje, N., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2013) · Blood · doi:10.1182/blood-2012-08-448548 · Cited by 393
Toh, B., Wang, X., Keeble, J., Sim, W. J., Khoo, K., Wong, W.-C., Kato, M., Prevost-Blondel, A., Thiery, J.-P., & Abastado, J.-P. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001162 · Cited by 369
The metastasis-promoting roles of tumor-associated immune cells
Smith, H. A., & Kang, Y. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1021-5 · Cited by 367
Chemokines in health and disease
Raman, D., Sobolik-Delmaire, T., & Richmond, A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.01.005 · Cited by 366
Raychaudhuri, B., Rayman, P., Ireland, J., Ko, J., Rini, B., Borden, E. C., Garcia, J., Vogelbaum, M. A., & Finke, J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor042 · Cited by 359
Meyer, C., Sevko, A., Ramacher, M., Bazhin, A. V., Falk, C. S., Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108121108 · Cited by 346
Baglieri, J., Brenner, D. A., & Kisseleva, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071723 · Cited by 341
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Butterfield, L. H., & Najjar, Y. G. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00973-8 · Cited by 330
Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas
Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0230 · Cited by 329
Targeting inflammasome/IL-1 pathways for cancer immunotherapy
Guo, B., Fu, S., Zhang, J., Liu, B., & Li, Z. (2016) · Scientific Reports · doi:10.1038/srep36107 · Cited by 302
Khalili, J. S., Liu, S., Rodríguez-Cruz, T. G., Whittington, M., Wardell, S., Liu, C., Zhang, M., Cooper, Z. A., Frederick, D. T., Li, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1632 · Cited by 301
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
Finke, J., Ko, J., Rini, B., Rayman, P., Ireland, J., & Cohen, P. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.030 · Cited by 281
Adipose stem cells: biology and clinical applications for tissue repair and regeneration
Kokai, L. E., Marra, K., & Rubin, J. P. (2014) · Translational Research · doi:10.1016/j.trsl.2013.11.009 · Cited by 281
MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation
Wang, Y., Ding, Y., Guo, N., & Wang, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00172 · Cited by 281
Zhang, B., Wang, Z., Wu, L., Zhang, M., Li, W., Ding, J., Zhu, J., Wei, H., & Zhao, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057114 · Cited by 269
Li, L., Wang, L., Li, J., Fan, Z., Yang, L., Zhang, Z., Zhang, C., Yue, D., Qin, G., Zhang, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2460 · Cited by 266
S100A8 and S100A9: New Insights into Their Roles in Malignancy
Srikrishna, G. (2012) · Journal of Innate Immunity · doi:10.1159/000330095 · Cited by 258
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Stultz, J., & Fong, L. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00340-5 · Cited by 242
Noel, M., O’Reilly, E. M., Wolpin, B. M., Ryan, D. P., Bullock, A. J., Britten, C. D., Linehan, D. C., Belt, B. A., Gamelin, E. C., Ganguly, B., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00830-3 · Cited by 199
Stiff, A., Trikha, P., Wesolowski, R., Kendra, K., Hsu, V., Uppati, S., McMichael, E., Duggan, M., Campbell, A., Keller, K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1490 · Cited by 188
Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis
Matsuda, M., & Seki, E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708876 · Cited by 189
“145,146 The MDSC number is well correlated with HCC tumor size.”
Michaeli, J., Shaul, M. E., Mishalian, I., Hovav, A.-H., Levy, L., Zolotriov, L., Granot, Z., & Fridlender, Z. G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356965 · Cited by 159
Michels, T., Shurin, G. V., Naiditch, H., Sevko, A., Umansky, V., & Shurin, M. R. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.642418 · Cited by 158
Geis-Asteggiante, L., Belew, A. T., Clements, V. K., Edwards, N. J., Ostrand-Rosenberg, S., El-Sayed, N. M., & Fenselau, C. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00646 · Cited by 104
Self-citationTai, L.-H., Alkayyal, A. A., Leslie, A. L., Sahi, S., Bennett, S., Tanese de Souza, C., Baxter, K., Angka, L., Xu, R., Kennedy, M. A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1431082 · Cited by 101
“MDSC display a diverse array of phenotypic markers and are defined by their subtype and associated suppressive activity.(16) Granulocytic MDSC (gMDSC) exert immune suppression through production of reactive oxygen species (ROS) by NAPDH oxidases which catalyzes the nitration of the T cell receptor, while monocytic MDS…”
BackgroundSingh, U. P., Singh, N. P., Singh, B., Hofseth, L. J., Taub, D. D., Price, R. L., Nagarkatti, M., & Nagarkatti, P. S. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.07.236 · Cited by 92
Vahidian, F., Duijf, P. H. G., Safarzadeh, E., Derakhshani, A., Baghbanzadeh, A., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.004 · Cited by 75
Maenhout, S. K., Thielemans, K., & Aerts, J. L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.956579 · Cited by 74
Jin, Y., An, X., Mao, B., Sun, R., Kumari, R., Chen, X., Shan, Y., Zang, M., Xu, L., Muntel, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07153-z · Cited by 73
Katara, G. K., Kulshrestha, A., Jaiswal, M. K., Pamarthy, S., Gilman-Sachs, A., & Beaman, K. D. (2016) · Oncogene · doi:10.1038/onc.2015.159 · Cited by 34
Metadata
- Authors
- Ostrand-Rosenberg, S.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2010-04-23
- Volume
- 59
- Issue
- 10
- Pages
- 1593-1600
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2011627030
- Cited by
- 521
- References
- 68
- FWCI
- 18.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.